ROIV
ROIVANT SCIENCES LTD
ROIVANT SCIENCES LTD historical holders
total: 3
Viking Global Investors ROIVANT SCIENCES LTD transactions over time
- Total transactions:
- 12
- New positions:
- 1
- Added:
- 1
- Reduced:
- 10
- Held since:
- 2021 Q4
- Held for:
- 18 quarters
- Latest activity:
- 2026 Q1
Ole Andreas Halvorsen has been an institutional investor in ROIVANT SCIENCES LTD (ROIV) since 2021 Q4. According to 2026 Q1 report, Ole Andreas Halvorsen holds 6,652,448 shares with a market value of roughly $184.27M representing 0.52% of their equity portfolio. The fund/company first acquired ROIV in 2021 Q4, initially purchasing about 88.24M shares. Since the initial investment, Viking Global Investors has made 11 more transactions in this position.
Does Ole Andreas Halvorsen still hold ROIV?
Yes, Ole Andreas Halvorsen continues to hold ROIVANT SCIENCES LTD (ROIV). According to their 2026 Q1 report, they maintain a position of 6,652,448 shares valued at approximately $184.27M, representing 0.52% of their equity portfolio.
When did Ole Andreas Halvorsen first invest in ROIV?
Ole Andreas Halvorsen first invested in ROIVANT SCIENCES LTD (ROIV) in 2021 Q4 at the reported quarter-end price of $10.08 per share, acquiring 88,238,700 shares in their initial purchase.
What is Ole Andreas Halvorsen's average cost basis for ROIV?
Based on historical transaction data, Ole Andreas Halvorsen's estimated cost basis for ROIVANT SCIENCES LTD (ROIV) is approximately $10.12 per share. This represents their average reported price* across all buy transactions.
Estimated cost basis*
- Weighted AVG buy price:
- $10.12
- Weighted AVG sell price:
- $13.84
ROIV transactions history by Viking Global Investors
12 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2026 Q1
|
0.52%
|
6,652,448
|
$27.70
|
$184,272,810
|
+3.25% (+209,257)
|
+0.02%
|
|
2025 Q4
|
0.37%
|
6,443,191
|
$21.70
|
$139,817,245
|
-72.69% (-17,151,640)
|
-0.97%
|
|
2025 Q3
|
0.93%
|
23,594,831
|
$15.13
|
$356,989,793
|
-31.09% (-10,642,948)
|
-0.47%
|
|
2025 Q2
|
1.12%
|
34,237,779
|
$11.27
|
$385,859,769
|
-25.59% (-11,775,973)
|
-0.42%
|
|
2025 Q1
|
1.48%
|
46,013,752
|
$10.09
|
$464,278,758
|
-3.76% (-1,796,208)
|
-0.06%
|
|
2024 Q4
|
1.83%
|
47,809,960
|
$11.83
|
$565,591,827
|
-11.63% (-6,289,106)
|
-0.27%
|
|
2024 Q3
|
2.28%
|
54,099,066
|
$11.54
|
$624,303,222
|
-21.77% (-15,056,780)
|
-0.67%
|
|
2024 Q2
|
2.81%
|
69,155,846
|
$10.57
|
$730,977,292
|
-0.31% (-213,115)
|
-0.01%
|
|
2023 Q4
|
2.85%
|
69,368,961
|
$11.23
|
$779,013,432
|
-5.54% (-4,065,340)
|
-0.19%
|
|
2023 Q3
|
3.48%
|
73,434,301
|
$11.68
|
$857,712,636
|
-2.40% (-1,804,399)
|
-0.09%
|
|
2023 Q2
|
3.10%
|
$10.08
|
-14.73% (-13,000,000)
|
|||
|
2021 Q4
|
2.56%
|
$10.08
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.